兔眼玻璃体内注射贝伐单抗的安全性。
Safety of intravitreal injection of bevacizumab in rabbit eyes.
作者信息
Feiner Leonard, Barr Emily E, Shui Ying-Bo, Holekamp Nancy M, Brantley Milam A
机构信息
Department of Ophthalmology and Visual Sciences/Campus Box 8096, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA.
出版信息
Retina. 2006 Oct;26(8):882-8. doi: 10.1097/01.iae.0000230717.85319.f5.
PURPOSE
To evaluate the safety of intravitreal injection of bevacizumab in rabbits using electrophysiological testing and histopathologic analysis.
METHODS
New Zealand albino rabbits were injected in one eye with control antibody (n = 2), 0.05 mL of bevacizumab (n = 3), or 0.2 mL of bevacizumab (n = 3). Electroretinograms were obtained 1 week and 4 weeks after injection. Histologic analysis was performed after completion of the electroretinographic studies.
RESULTS
No statistical differences were seen in scotopic and photopic a- and b-wave amplitudes between untreated control and bevacizumab-injected eyes. No histopathologic differences were identified between untreated control and bevacizumab-injected eyes.
CONCLUSION
Our study did not find evidence of retinal toxicity from a single intravitreal injection of bevacizumab in rabbits.
目的
采用电生理检测和组织病理学分析评估玻璃体内注射贝伐单抗对兔眼的安全性。
方法
将新西兰白化兔一只眼注射对照抗体（n = 2）、0.05 mL贝伐单抗（n = 3）或0.2 mL贝伐单抗（n = 3）。在注射后1周和4周记录视网膜电图。在视网膜电图研究完成后进行组织学分析。
结果
未治疗的对照眼和注射贝伐单抗的眼之间，暗视和明视a波和b波振幅无统计学差异。未治疗的对照眼和注射贝伐单抗的眼之间未发现组织病理学差异。
结论
我们的研究未发现兔眼单次玻璃体内注射贝伐单抗有视网膜毒性的证据。
Zotero 插件